Access the Fast Growing Asia-Pacific Clinical Trials Market With the Largest CRO in Japan

Get to the Market Faster with CMIC’s Premier Clinical Trial Services

Is your goal to effectively introduce your product to the market? Do you need a single partner to support development, clinical trial services, commercialization, and more?

CMIC Group can be your reliable partner. As the largest CRO in Japan, we take pride in supporting clinical trials across more than 13 countries in the Asia South Pacific region. Over the past 5 years, we have supported clinical trials over a range of therapeutic areas.

Areas We Support

While these are just some of the areas we support, we are not limited, as we are a full-service clinical research organization with a dynamic range of expertise and resources at your disposal.

Why consider the Asia Pacific Region for Your Clinical Trials?

The Asia-Pacific region offers several advantages that make it an attractive destination for clinical trials. With its vast population, diverse demographics, and cutting-edge research institutions, an increasing number of pharmaceutical and biotech companies are seeking to conduct clinical trials in Asia.

See why leading pharmaceutical and biotech companies trust CMIC for their Asia-Pacific clinical trials. Our clients consistently praise our expertise, speed, and commitment to success.

Unlock the Benefits of Clinical Trials in Asia – Check our Guide to Learn More!
Clinical Trials in Asia Key Takeaways

Access the Lucrative Japanese Pharmaceutical Market with Japan’s Leading ICCC & MAH Provider

Fast-Track Regulatory Approval and Commercialization with our End-to-End Support

Do you need an expert support for your clinical trials and product commercialization in Japan? Are you looking to have one trusted partner for all stages towards your success?

CMIC Group provides full-services support for pharmaceutical companies entering Japan market. Our experienced consultants help you determine the best strategy, navigating Japan’s unique regulations and environment. We offer options for entry at any stage of drug development, whether you’re starting clinical trials, planning regulatory approval, or commercializing an approved product.

The Japanese pharmaceutical market offers significant growth opportunities, driven by a streamlined regulatory process and high demand for innovative therapies. Benefit from faster approval times and predictable reimbursement, accelerating your product’s path to market.

How CMIC Group will Support Your Japan Market Journey?

CMIC can support your Japan market entry no matter which pathway you choose: establishing a subsidiary, licensing out, or assigning CMIC as your MAH.

We are also the only company in Japan offering MAH partnering for orphan drugs through our Orphan Pacific Inc. subsidiary.

Learn how CMIC’s expertise and dedicated support have helped companies overcome the challenges of Japan market entry and achieve their goals.

Experts from leading clinical sites in Japan, global sponsors and CMIC Group shared insights and real-life examples of patient recruitment, site selection, clinical trial execution and regulatory navigation in Japan.

Don’t miss this opportunity to learn how your company can successfully tap into the Japanese market and accelerate drug development – Watch this free resource today!